Generated by AI
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapies for cancer. The company concentrates on oncology programs that target angiogenesis, immune activation, and tumor-driven immunosuppression, with product candidates designed to address critical biological pathways involved in anti-tumor responses. Its current pipeline includes bispecific and monoclonal antibody programs such as tovecimig, CTX-471, CTX-8371, and CTX-10726, reflecting a platform built around antibody discovery and engineering. Compass Therapeutics uses proprietary technologies to identify and optimize therapeutic leads and to create modular, manufacturable bispecific candidates. The company plays a specialized role in the biotechnology market by advancing immuno-oncology research into clinical development, with a focus on solid tumors and other cancer indications.
Website80 Guest Street
Boston, MA, 02135
United States
The latest articles about CMPX.
Summary of Nov 17's posts. Generated by AI.
Summary of Nov 17's posts. Generated by AI.
Summary of May 1's posts. Generated by AI.
Summary of Nov 17's posts. Generated by AI.
Investors talking about CMPX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.